LifeMD, Inc. (LFMD) got here out with a quarterly lack of $0.38 per share versus the Zacks Consensus Estimate of a lack of $0.44. This compares to lack of $0.25 per share a 12 months in the past. These figures are adjusted for non-recurring gadgets.
This quarterly report represents an earnings shock of 13.64%. 1 / 4 in the past, it was anticipated that this firm would submit a lack of $0.27 per share when it truly produced a lack of $2.56, delivering a shock of -848.15%.
Over the past 4 quarters, the corporate has surpassed consensus EPS estimates simply as soon as.
LifeMD, Inc.Which belongs to the Zacks Medical Companies business, posted revenues of $18.2 million for the quarter ended March 2021, lacking the Zacks Consensus Estimate by 0.12%. This compares to year-ago revenues of $4.31 million. The corporate has not been in a position to beat consensus income estimates over the past 4 quarters.
The sustainability of the inventory’s speedy value motion based mostly on the recently-released numbers and future earnings expectations will principally rely on administration’s commentary on the earnings name.
LifeMD, Inc. Shares have added about 5.4% because the starting of the 12 months versus the S&P 500’s acquire of 8.2%.
What’s Subsequent for LifeMD, Inc.
Whereas LifeMD, Inc. Has underperformed the market up to now this 12 months, the query that involves traders’ minds is: what’s subsequent for the inventory?
There are not any straightforward solutions to this key query, however one dependable measure that may assist traders tackle that is the corporate’s earnings outlook. Not solely does this embody present consensus earnings expectations for the approaching quarter(s), but additionally how these expectations have modified recently.
Empirical analysis exhibits a powerful correlation between near-term inventory actions and tendencies in earnings estimate revisions. Traders can observe such revisions by themselves or depend on a tried-and-tested ranking instrument just like the Zacks Rank, which has a powerful observe document of harnessing the ability of earnings estimate revisions.
Forward of this earnings launch, the estimate revisions development for LifeMD, Inc. Was unfavorable. Whereas the magnitude and route of estimate revisions may change following the corporate’s just-released earnings report, the present standing interprets right into a Zacks Rank #4 (Promote) for the inventory. So, the shares are anticipated to underperform the market within the close to future. You possibly can see the whole record of at present’s Zacks #1 Rank (Robust Purchase) shares right here.
It will likely be attention-grabbing to see how estimates for the approaching quarters and present fiscal 12 months change within the days forward. The present consensus EPS estimate is -$0.35 on $21.1 million in revenues for the approaching quarter and -$1.48 on $87.16 million in revenues for the present fiscal 12 months.
Traders needs to be aware of the truth that the outlook for the business can have a fabric impression on the efficiency of the inventory as nicely. By way of the Zacks Business Rank, Medical Companies is at the moment within the backside 28% of the 250 plus Zacks industries. Our analysis exhibits that the highest 50% of the Zacks-ranked industries outperform the underside 50% by an element of greater than 2 to 1.
Need the newest suggestions from Zacks Funding Analysis? Right now, you’ll be able to obtain 7 Greatest Shares for the Subsequent 30 Days. Click on to get this free report
LifeMD, Inc. (LFMD): Free Inventory Evaluation Report
To learn this text on Zacks.com click on right here.
Zacks Funding Analysis
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.